Imatinib

Drugs

Volumn 61, Issue 12, 2001, Pages 1765-1774

  Lyseng Williamson, K ^a   Jarvis, B ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALPHA INTERFERON; ALPHA1 GLYCOPROTEIN; AMINO ACID; BCR ABL PROTEIN; CARBAMAZEPINE; CLARITHROMYCIN; CYTARABINE; CYTOCHROME P450; DAUNORUBICIN; DEXAMETHASONE; ERYTHROMYCIN; ETOPOSIDE; GLYCOPROTEIN P; HEMOGLOBIN; IMATINIB; ITRACONAZOLE; KETOCONAZOLE; MAFOSFAMIDE; PHENOBARBITAL; PHENYTOIN; PLASMA PROTEIN; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; RETINOIC ACID; RIFAMPICIN; STEM CELL FACTOR; STEM CELL FACTOR RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE;

ASCITES; BLAST CELL CRISIS; BONE MARROW TRANSPLANTATION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOGENETICS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG TOLERABILITY; EDEMA; EFFUSION; GASTROINTESTINAL TUMOR; HUMAN; LIVER TOXICITY; MUSCLE CRAMP; NAUSEA AND VOMITING; NEUTROPENIA; PHILADELPHIA 1 CHROMOSOME; PROGNOSIS; REVIEW; THROMBOCYTOPENIA;

EID: 0034775647     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200161120-00007     Document Type: Review

References (50)

1. Chronic myelogenous leukemia
2. Chronic myeloid leukemia
3. Evaluation of the safety and efficacy of an oral molecularly-targeted therapy, STI571, in patients (Pts) with unresectable or metastatic gastrointestinal stromal tumors (GISTS) expressing C-KIT (CD117)
4. STI571, an active drug in metastatic gastro intestinal stromal tumors (GIST), an EORTC Phase I study
5. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor
6. Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase
7. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
8. + leukemic cells and induces apoptosis
9. CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs
10. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells
11. The tyrosine kinase inhibitor STI571, like interferon-α, preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors from patients with chronic myeloid leukemia
12. ARG tyrosine kinase activity is inhibited by ST1571
13. r 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148)
14. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins
15. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor
16. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth
17. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571
18. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-Kit and platelet-derived growth factor receptors
19. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor
20. Growth-inhibitory effect of STI571 on cells transformed by the COLIA1/PDGFB rearrangement
21. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenyl-aminopyrimidine derivative
22. TEL/PDGFßR induces hematologic malignancies in mice that respond to a specific tyrosine kinase inhibitor
23. Synergistic activity of STI571 with chemotherapeutic drugs and irradiation
24. Efficacy of STI571, an Abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against Bcr-Abø-positive cells
25. Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells
26. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents
27. Sti571 induced apoptosis in Philadelpia chromosome-positive chronic myeloid leukemia blasts is increased by daunorubicin
28. Tyrosine kinase inhibitor STI571 potentiates the pharmacologic activity of retinoic acid in acute promyelocytic leukemia cells: Effects on the degradation of RARα and PML-RARα
29. The dermato-fibrosarcoma protuberans-associated collagen type Iα1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB
30. Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class
31. Blockade of PDGF-R signaling by STI571 inhibits angiogenesis and growth of human protsate cancer cells in the bone of nude mice
32. Alpha-1-acid glycoprotein as expressed in chronic myeloid leukemia does not mediate significant in vitro resistance to STI571
33. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
34. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
35. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
36. + leukemia patients treated with an ABL-specific kinase inhibitor is associated with reactivation of BCR-ABL
37. BCR/ABL gene amplification: A possible mechanism of drug resistance in patients treated with an ABL-specific kinase inhibitor
38. Molecular and chromosomal mechanisms of resistance in CML patents after STI571 (Glivec) monotherapy
39. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor ST1571: Diverse mechanisms of resistance
40. Clinical pharmacokinetics and pharmacodynamics of ST1571 in a phase I trial in chronic myelogenous leukemia (CML) patients
41. Effect of food on STI571 GLivec pharmacokinetics and bioavailability
42. A phase II study to determine the safety and anti-leukemic effects of ST1571 in patients with Philadelphia chromosome positive chronic myeloid leukemia in myeloid blast crisis
43. A phase II study to determine the safety and anti-leukemic effects of STI571 in adult patients with Philadelphia chromosome positive acute leukemias
44. A phase II study of STI 571 in adult patients with Philadelphia chromosome positive chronic myeloid leukemia in accelerated phase
45. Phase II study of STI571, a tyrosine kinase inhibitor, in patients (pts) with resistant or refractory Philadelphia chromosome-positive chronic myeloid leukemia (Ph+CML)
46. Glivec (imatinib mesylate, STI571) induces hematologic and cytogenetic responses in patients with chronic myeloid leukemia in myeloid blast crisis: Results of a multicenter phase II study
47. Treatment of adult Philadelphia chromosome positive chronic myeloid leukaemia (CML) in accelerated phase with STI571: Update of phase II results
48. Glivec (imatinib mesylate, STI571) induces hematologic and cytogenetic responses in the majority of patients with chronic myeloid leukemia in late chronic phase: Results of a phase II study